A
Abeer M Shaaban
Researcher at Queen Elizabeth Hospital Birmingham
Publications - 191
Citations - 3971
Abeer M Shaaban is an academic researcher from Queen Elizabeth Hospital Birmingham. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 31, co-authored 152 publications receiving 3106 citations. Previous affiliations of Abeer M Shaaban include Leeds General Infirmary & University Hospitals Birmingham NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Progress towards unlocking the secrets of oestrogen receptor beta in breast cancer
Valerie Speirs,Parker,Andrew R. Green,Ian O. Ellis,Andrew M. Hanby,Ptk Saunders,Abeer M Shaaban +6 more
TL;DR: Cytoplasmic staining of ERβ, whether alone or in combination with nuclear staining, was associated with decreased overall survival and this study highlighted the importance of cytoplasmaic expression of ER β in dictating outcome.
Journal ArticleDOI
Metastatic "Ductal Carcinoma In Situ-Like" Lobular Carcinoma in a Lymph Node: A Case Report and Review of the Literature
TL;DR: The case suggests that lobular carcinoma can morphologically recreate a primary microenvironment at a distant site and simulate in situ growth and recognition of this pattern is important to avoid misdiagnosis.
Journal ArticleDOI
Adverse effects of dyes used in sentinel node biopsy on immunocytochemical determination of hormone receptors in breast cancer cells.
Yazan Masannat,Abeer M Shaaban,Valerie Speirs,G Coast,P. Jackson,Kieran Horgan,Andrew M. Hanby +6 more
TL;DR: Given the importance of the determination of ERα expression in the treatment of breast cancer and the wider use of SLNB to stage the axilla, it is investigated whether the dyes used change the immunocytochemical profile of these receptors.
Journal ArticleDOI
Abstract OT1-04-01: ATNEC: A multi-centre, randomised trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the lymph glands after neoadjuvant chemotherapy (clinicaltrials.gov: nct04109079)
Amit Goyal,Sophie Cramp,Andrea Marshall,Duncan Wheatley,Natalie Hammonds,Shama Puri,Tara Homer,Luke Vale,R. Butt,Romaana Mir,Jan Rose,Helen Teresa Edwards,Samreen Ahmed,Abeer M Shaaban,B. Elsberger,Julie Bruce,S Gasson,Valerie Speirs,Jacqui Shaw,Helen B Higgins,Janet A. Dunn +20 more
TL;DR: To assess whether, omitting further axillary treatment for patients with early stage breast cancer and axillary nodal metastases on needle biopsy - who after NACT have no residual nodal disease on SNB - is non-inferior to axillarytreatment in terms of disease free survival, and reduces the risk of lymphoedema at 5 years.
Journal ArticleDOI
Radiation-Associated Primary Osteosarcoma of the Breast.
TL;DR: Post-irradiation osteosarcoma should be considered in the differential diagnosis of breast lesions showing malignant osteoid, according to the lack of epithelial/glandular differentiation, in situ carcinoma or leaf-like pattern.